Business Wire

Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...
Business Wire

Results from a Phase 3 Study of Once-Monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
STAT

New long-acting injectable helps manage schizophrenia or bipolar I symptoms for two-months

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...
News Medical

Abilify Asimtufii

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Abilify Asimtufii? Abilify Asimtufii contains the ...
Reuters

Abilify helps as add-on depression treatment-study

NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...
Science Daily

Elucidating the mechanism of aripiprazole action in treating circadian rhythm sleep disorders

Aripiprazole enhances the entrainment to external light-dark cycles by weakening the synchronization between neurons in the central circadian clock, thereby improving the symptoms of circadian rhythm ...